Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
- Registration Number
- NCT02395172
- Brief Summary
The main purpose of this study was to demonstrate superiority with regard to overall survival of avelumab versus docetaxel in participants with programmed death ligand 1 (PD-L1) positive, non-small cell lung cancer (NSCLC) after failure of a platinum-based doublet.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 792
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Avelumab Avelumab - Docetaxel Docetaxel -
- Primary Outcome Measures
Name Time Method Overall Survival (OS) Time in Programmed Death Ligand 1 (PD-L1) + Full Analysis Set Population (FAS) Time from date of randomization up to 1420 days The OS time was defined as the time from randomization to the date of death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
- Secondary Outcome Measures
Name Time Method Progression-Free Survival (PFS) Time in Full Analysis Set Population Time from date of randomization up to 907 days PFS was defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PFS was assessed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as adjudicated by independent endpoint review committee (IERC). PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions and unequivocal progression of non-target lesions. PFS was measured using Kaplan-Meier (KM) estimates.
Progression-Free Survival (PFS) Time in PD-L1+ Full Analysis Set Population Time from date of randomization up to 907 days PFS was defined as the time from date of randomization until date of the first documentation of progressive disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PFS was assessed as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as adjudicated by independent endpoint review committee (IERC). PD was defined as at least a 20 percent (%) increase in the sum of longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions and unequivocal progression of non-target lesions. PFS was measured using Kaplan-Meier (KM) estimates.
Percentage of Participants With Objective Response as Assessed by Independent Endpoint Review Committee (IERC) in Full Analysis Set Population Time from date of randomization up to 907 days Percentage of participants with objective response (CR plus PR) according to RECIST v1.1 was reported. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.
Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire Through Composite Index Score at End of Treatment (EOT) Baseline, End of treatment visit (up to Week 124) The EQ-5D-5L health outcome questionnaire was a measure of health status that provides a simple descriptive profile and a single index value. The EQ-5D-5L defined health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items were combined to generate health profiles. These profiles were converted to a continuous single index score. The lowest possible score was -0.59 (unable to walk, unable to self-care, unable to do usual activities, extreme pain or discomfort, extreme anxiety or depression) and the highest was 1.00 (no problems in all 5 dimensions).
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) Baseline, End of treatment visit (up to Week 124) EORTC QLQ-C30 was a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. It consisted of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). The EORTC QLQ-C30 GHS/QoL score ranged from 0 to 100; High score indicated better GHS/QoL. Score 0 represents: very poor physical condition and QoL. Score 100 represents: excellent overall physical condition and QoL.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Severity Time from date of randomization up to 1420 days Treatment Emergent Adverse Events were graded as per National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03 (NCI-CTCAE v 4.03). Grade 3 refers to severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care and Activity of daily living (ADL), Grade 4 refers to Life-threatening consequences; where urgent intervention indicated, Grade 5 refers to the death related to adverse event.
Overall Survival (OS) Time in Full Analysis Set Population Time from date of randomization up to 1420 days The OS time was defined as the time from randomization to the date of death. The participants who were still alive at the time of data analysis or who were lost to follow-up OS time was censored at the last recorded date that the participant was known to be alive before the data cutoff date. OS was measured using Kaplan-Meier (KM) estimates.
Number of Participants With Confirmed Best Overall Response (BOR) as Assessed by Independent Endpoint Review Committee (IERC) in PD-L1+ Full Analysis Set Population Time from date of randomization up to 907 days Confirmed BOR was determined according to RECIST v1.1 and as adjudicated by an IERC. Confirmed BOR was defined as the best response of any of the complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) recorded from the date of randomization until disease progression or recurrence (taking the smallest measurement recorded since the start of treatment as reference). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions and unequivocal progression of non-target lesions. Number of participants with best overall response in each category (CR, PR, SD, PD) was reported.
Percentage of Participants With Objective Response as Assessed by Independent Endpoint Review Committee (IERC) in PD-L1+ Full Analysis Set Population Time from date of randomization up to 907 days Percentage of participants with objective response (CR plus PR) according to RECIST v1.1 was reported. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions.
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance: Baseline Score vs. Worst Post-baseline Score Time from date of randomization up to 1420 days ECOG performance status measured to assess participant's performance status on a scale of 0 to 5, where 0 = Fully active, able to carry on all pre-disease activities without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out light or sedentary work; 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; 3 = Capable of only limited self-care, confined to bed/chair for more than 50 percent of waking hours; 4 = Completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5 = dead. The participants with missing worst post baseline score were also reported. ECOG performance status was reported in terms of number of participants with Baseline value vs. worst post-baseline value (i.e. highest score) combination.
Number of Participants With Confirmed Best Overall Response (BOR) as Assessed by an Independent Endpoint Review Committee (IERC) in Full Analysis Set Population Time from date of randomization up to 907 days Confirmed BOR was determined according to RECIST v1.1 and as adjudicated by an IERC. Confirmed BOR was defined as the best response of any of the complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) recorded from the date of randomization until disease progression or recurrence (taking the smallest measurement recorded since the start of treatment as reference). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: Neither sufficient increase to qualify for PD nor sufficient shrinkage to qualify for PR. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions and unequivocal progression of non-target lesions. Number of participants with best overall response in each category (CR, PR, SD, PD) was reported.
Change From Baseline in European Quality of Life 5-dimensions (EQ-5D-5L) Health Outcome Questionnaire Through Visual Analogue Scale (VAS) at End of Treatment (EOT) Baseline, End of treatment visit (up to Week 124) EQ-5D-5L was comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses were used to derive overall score using a visual analog scale (VAS) that ranged from 0 to 100 millimeter (mm), where 0 was the worst health you can imagine and 100 was the best health you can imagine.
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) Baseline, End of treatment visit (up to Week 124) EORTC QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The EORTC QLQ-LC13 module generated one multiple-item score assessing dyspnea and a series of single item scores assessing coughing, hemoptysis, sore mouth, dysphagia, neuropathy, alopecia, pain in chest, pain in arms or shoulder and pain in other parts. Score range: 0 (no burden of symptom domain or single symptom item) to 100 (highest burden of symptoms for symptom domains and single items).
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), Drug Related Treatment Emergent Adverse Events and Treatment Emergent Adverse Events Leading to Death Time from date of randomization up to 1420 days An Adverse event (AE) was defined as any unfavorable and unintended sign (including clinically significant abnormal laboratory, vital signs and 12-lead Electrocardiogram findings), symptom, or disease temporally associated with the use of study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent events were the events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state up to 30 days after last administration. TEAEs included both Serious TEAEs and non-serious TEAEs.
Number of Participants With Positive Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) for Avelumab Time from date of randomization up to 1420 days Serum samples were analyzed by a validated electrochemiluminesce immunoassay to detect the presence of antidrug antibodies (ADA). Samples that screened positive were subsequently tested in a confirmatory assay were tested for neutralizing antibodies (nAb). Number of participants with ADA or nAb positive results for Avelumab were reported.
Trial Locations
- Locations (259)
Hemato Oncologos S.A.
🇨🇴Cali, Colombia
Healing Hands Oncology and Medical Care
🇺🇸Lawndale, California, United States
Hospital Universitario Austral
🇦🇷Pilar, Argentina
CEPON - Centro de Pesquisas Oncológicas de Santa Catarina
🇧🇷Florianópolis, Brazil
Penn State Univ. Milton S. Hershey Medical Center
🇺🇸Hershey, Pennsylvania, United States
Lynn Cancer Institute Center
🇺🇸Boca Raton, Florida, United States
Abington Memorial Hospital
🇺🇸Abington, Pennsylvania, United States
Clínica Universitaria Privada Reina Fabiola
🇦🇷Barrio General Paz, Argentina
Instituto Medico Especializado Alexander Fleming
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Sanatorio Parque S.A.
🇦🇷Rosario, Argentina
Grand Hôpital de Charleroi
🇧🇪Gilly, Belgium
C. H. U. Sart Tilman
🇧🇪Liège, Belgium
Pacific Cancer Medical Center, Inc.
🇺🇸Anaheim, California, United States
Florida Cancer Specialists-Broadway
🇺🇸Fort Myers, Florida, United States
Ballarat Base Hospital
🇦🇺Ballarat, Australia
University of Alabama
🇺🇸Tuscaloosa, Alabama, United States
Lyell McEwin Hospital
🇦🇺Elizabeth Vale, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Australia
Signal Point Clinical Research Center
🇺🇸Middletown, Ohio, United States
Florida Cancer Specialists
🇺🇸West Palm Beach, Florida, United States
Centro de Oncologia e Investigacion Buenos Aires
🇦🇷Berazategui, Argentina
CEMIC
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Shato, Ead
🇧🇬Sofia, Bulgaria
Instituto de Terapias Oncologicas Providencia
🇨🇱Santiago, Chile
Coffs Harbour Base Hospital
🇦🇺Coffs Harbour, Australia
FALP - Fundación Arturo López Pérez
🇨🇱Santiago, Chile
ICO - Site Paul Papin
🇫🇷Angers Cedex 9, France
Instituto Clinico Oncologico del Sur (ICOS)
🇨🇱Temuco, Chile
Instituto de Cancerologia S.A.
🇨🇴Medellin, Colombia
Hospital Pablo Tobón Uribe
🇨🇴Medellín, Colombia
Clínica de Neoplasias Litoral Ltda.
🇧🇷Itajaí, Brazil
Royal Melbourne Hospital
🇦🇺Parkville, Australia
Lismore Base Hospital
🇦🇺Lismore, Australia
Instituto DAMIC Fundacion Rusculleda
🇦🇷Cordoba, Argentina
Centro Oncologico de Parana
🇦🇷Parana, Argentina
UZ Leuven
🇧🇪Leuven, Belgium
Centro de Investigaciones Clinicas Viña del Mar
🇨🇱Viña del Mar, Chile
Cenantron - Centro Avançado de Tratamento Oncológico S/C Ltda
🇧🇷Belo Horizonte, Brazil
Fundación Valle del Lilí
🇨🇴Cali, Colombia
Sapir Medical Center, Meir Hospital
🇮🇱Kfar-Saba, Israel
St John of God Hospital
🇦🇺Subiaco, Australia
MHAT "Serdika", EOOD
🇧🇬Sofia, Bulgaria
Hospital Clinico Viña del Mar
🇨🇱Viña del Mar, Chile
Fundacion Cardioinfantil Instituto de Cardiologia
🇨🇴Bogota, Colombia
CHU Poitiers - Hôpital la Milétrie
🇫🇷Poitiers, France
IPS IMAT- Instituto Medico de Alta Tecnologia - Oncomedica S.A.
🇨🇴Monteria, Colombia
Tudogyogyintezet Torokbalint
🇭🇺Torokbalint, Hungary
Masarykuv onkologicky ustav
🇨🇿Brno, Czechia
Multiscan s.r.o.
🇨🇿Pardubice, Czechia
Fundação Faculdade Regional de Medicina de São José do Rio Preto
🇧🇷São José do Rio Preto, Brazil
Complex Oncological Center - Plovdiv, EOOD
🇧🇬Plovdiv, Bulgaria
CIEC - Centro Internacional de Estudios Clínicos
🇨🇱Santiago, Chile
CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia
🇧🇷Santo André, Brazil
Instituto Nacional de Cancerologia E.S.E.
🇨🇴Bogota, Colombia
Administradora Country S.A.
🇨🇴Bogotá, Colombia
Nemocnice Novy Jicin a.s.
🇨🇿Novy Jicin, Czechia
Vseobecna fakultni nemocnice V Praze
🇨🇿Praha 2, Czechia
Centro Medico Imbanaco
🇨🇴Cali, Colombia
General Hospital Zadar
🇭🇷Zadar, Croatia
Hospital São Lucas da PUCRS
🇧🇷Porto Alegre, Brazil
IOS - Instituto de Oncologia de Sorocaba "Dr. Gilson Delgado"
🇧🇷Sorocaba, Brazil
MHAT 'Tokuda Hospital Sofia', AD
🇧🇬Sofia, Bulgaria
Clinica Colsanitas S.A. sede Clinica Universitaria Colombia
🇨🇴Bogota, Colombia
The Lady Davis Carmel Medical Center
🇮🇱Haifa, Israel
Chaim Sheba Medical Center
🇮🇱Ramat-Gan, Israel
National Cancer Center Hospital
🇯🇵Chuo-ku, Japan
Centre Catherine de Sienne
🇫🇷Nantes, France
ICO - Site René Gauducheau
🇫🇷Saint Herblain, France
Saitama Cancer Center
🇯🇵Kitaadachi-gun, Japan
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milano, Italy
COI - Clínicas Oncológicas Integradas
🇧🇷Rio de Janeiro, Brazil
Semmelweis Egyetem AOK
🇭🇺Budapest, Hungary
Thomayerova nemocnice
🇨🇿Praha 4, Czechia
Miskolci Semmelweis Korhaz es Egyetemi Oktatokorhaz
🇭🇺Miskolc, Hungary
Hadassah University Hospital - Ein Kerem
🇮🇱Jerusalem, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
Hiroshima City Hiroshima Citizens Hospital
🇯🇵Hiroshima-shi, Japan
Uzsoki Utcai Korhaz
🇭🇺Budapest, Hungary
Ospedale Mater Salutis
🇮🇹Legnago (VR), Italy
Clinique Victor Hugo - Centre Jean Bernard
🇫🇷Le Mans Cedex 02, France
Centre Antoine Lacassagne
🇫🇷Nice cedex 02, France
CHU Strasbourg - Nouvel Hôpital Civil
🇫🇷Strasbourg, France
Petz Aladar Megyei Oktato Korhaz
🇭🇺Györ, Hungary
Osaka Medical Center for Cancer and Cardiovascular Diseases
🇯🇵Osaka-shi, Japan
Kitasato University Hospital
🇯🇵Sagamihara-shi, Japan
Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza
🇮🇹Roma, Italy
Rambam Health Care Campus
🇮🇱Haifa, Israel
Chonnam National University Hwasun Hospital
🇰🇷Hwasun-gun, Korea, Republic of
Rabin Medical Center-Beilinson Campus
🇮🇱Petach Tikva, Israel
NHO Kyushu Cancer Center
🇯🇵Fukuoka-shi, Japan
Osaka Prefectural Medical Center for Respiratory and Allergic Diseases
🇯🇵Habikino-shi, Japan
Miyagi Cancer Center
🇯🇵Natori-shi, Japan
Tokyo Medical University Hospital
🇯🇵Shinjuku-ku, Japan
Complejo Hospitalario Universitario de Santiago
🇪🇸Santiago de Compostela, Spain
Osaka City General Hospital
🇯🇵Osaka-shi, Japan
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Chungbuk National University Hospital
🇰🇷Cheongju-si, Korea, Republic of
Hospital de Mataro
🇪🇸Mataro, Spain
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
Centro Oncologico Estatal ISSEMyM
🇲🇽Toluca, Mexico
Hacettepe University Medical Faculty
🇹🇷Ankara, Turkey
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Clinica San Borja
🇵🇪Lima, Peru
Instituto Nacional de Enfermedades Neoplásicas
🇵🇪Lima, Peru
Hospital Universitario Ramon y Cajal
🇪🇸Madrid, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, United Kingdom
Ankara University Medical Faculty
🇹🇷Ankara, Turkey
Hospital Universitari i Politecnic La Fe
🇪🇸Valencia, Spain
Marmara University Pendik Research and Training Center
🇹🇷Istanbul, Turkey
Dokuz Eylul University Medicine Faculty
🇹🇷Izmir, Turkey
Konya Necmettin Erbakan University Meram Faculty of Medicine
🇹🇷Konya, Turkey
Royal Bournemouth General Hospital
🇬🇧Bournemouth, United Kingdom
University Cancer Institute
🇺🇸Boynton Beach, Florida, United States
Metairie Oncologist, LLC
🇺🇸Metairie, Louisiana, United States
Northeast Georgia Cancer Care, LLC
🇺🇸Athens, Georgia, United States
Hospital Italiano Regional del Sur
🇦🇷Bahia Blanca, Argentina
Instituto de Oncología de Rosario
🇦🇷Rosario, Argentina
Box Hill Hospital
🇦🇺Box Hill, Australia
Greenslopes Private Hospital
🇦🇺Greenslopes, Australia
Hospital Bruno Born
🇧🇷Lajeado, Brazil
Hospital Mãe de Deus
🇧🇷Porto Alegre, Brazil
UMHAT 'Dr. Georgi Stranski', EAD
🇧🇬Pleven, Bulgaria
MHAT 'Sv. Marina', EAD
🇧🇬Varna, Bulgaria
Clinical Hospital Centar "Sestre Milosrdnice"
🇭🇷Zagreb, Croatia
Hôpital Nord - AP-HM Marseille#
🇫🇷Marseille cedex 20, France
Soroka Medical Center
🇮🇱Beer Sheva, Israel
Assaf Harofeh Medical Center
🇮🇱Beer Yaakov, Israel
IEO Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Aichi Cancer Center Hospital
🇯🇵Okazaki-shi, Japan
Toyama University Hospital
🇯🇵Toyama-shi, Japan
Kanagawa Cancer Center
🇯🇵Yokohama-shi, Japan
Wakayama Medical University Hospital
🇯🇵Wakayama-shi, Japan
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Phylasis Clinicas Research S de RL de CV
🇲🇽Cuautitlan Izcalli, Mexico
The Catholic University of Korea, St. Vincent's Hospital
🇰🇷Suwon-si, Korea, Republic of
Fundacion Rodolfo Padilla Padilla, A.C.
🇲🇽Leon, Mexico
Instituto de Investigaciones Aplicadas a la Neurociencia A.C.
🇲🇽Durango, Mexico
Health Pharma Professional Research S.A. de C.V.
🇲🇽Mexico, Mexico
Winsett Rethman S.A. de C.V.
🇲🇽Monterrey, Mexico
Centro de Investigacion Clinica Chapultepec S.A. de C.V.
🇲🇽Morelia, Mexico
Oaxaca Site Management Organization S.C.
🇲🇽Oaxaca, Mexico
Clinica Monte Carmelo
🇵🇪Arequipa, Peru
Hospital Nacional Almanzor Aguinaga Asenjo
🇵🇪Chiclayo, Peru
Hospital Nacional Adolfo Guevara Velasco
🇵🇪Cusco, Peru
Hospital Nacional Guillermo Almenara Irigoyen
🇵🇪Lima, Peru
Clínica Ricardo Palma
🇵🇪Lima, Peru
Szpital Specjalistyczny W Brzozowie, Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza
🇵🇱Brzozow, Poland
Wojewodzkie Centrum Szpitalne Kotliny Jeleniogorskiej
🇵🇱Jelenia Gora, Poland
Samodzielny Publiczny Szpital Kliniczny nr 5 SUM
🇵🇱Katowice, Poland
Centrum Terapii Wspolczesnej J.M. Jasnorzewska sp. komandytowo-akcyjna
🇵🇱Lodz, Poland
KO-MED Centra Kliniczne Lublin II
🇵🇱Lublin, Poland
SSZZOZ im. Dr Teodora Dunina w Rudce
🇵🇱Mrozy, Poland
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy
🇵🇱Otwock, Poland
Spitalul Judetean de Urgenta Alba Iulia
🇷🇴Alba Iulia, Romania
Spitalul Judetean de Urgenta "Dr. Constantin Opris" Baia Mare
🇷🇴Baia Mare, Romania
Policlinica de Diagnostic Rapid SRL
🇷🇴Brasov, Romania
Spital Lotus SRL
🇷🇴Ploiesti, Romania
Spitalul Clinic Municipal "Dr. Gavril Curteanu" Oradea
🇷🇴Oradea, Romania
SHI "Republican Clinical Oncological Dispensary of HM RT"
🇷🇺Kazan, Russian Federation
S.C Oncocenter Oncologie Clinica S.R.L
🇷🇴Timisoara, Romania
FSBHI Clinical research institute of phthisiopulmonology
🇷🇺Saint Petersburg, Russian Federation
SHBI Moscow Clinical Scientific Center of Department of Healthcare of Moscow
🇷🇺Moscow, Russian Federation
Pavlov First Saint Petersburg State Medical University
🇷🇺Saint Petersburg, Russian Federation
St. Petersburg SHI "City Clinical Oncology Dispensary"
🇷🇺St. Petersburg, Russian Federation
FBI "Scientific Research Institute of Oncology n. a. N. N. Petrov"
🇷🇺St. Petersburg, Russian Federation
Univerzitna nemocnica Bratislava, Nemocnica Ruzinov
🇸🇰Bratislava, Slovakia
Nemocnica s poliklinikou Sv. Jakuba, n.o. Bardejov
🇸🇰Bardejov, Slovakia
Ustredna vojenska nemocnica SNP Ruzomberok- Fakultna nemocnica
🇸🇰Ruzomberok, Slovakia
Fakultna nemocnica Trnava
🇸🇰Trnava, Slovakia
GVI Cape Gate Oncology Centre
🇿🇦Cape Town, South Africa
GVI Rondebosch Oncology Centre
🇿🇦Cape town, South Africa
GVI Langenhoven Drive Oncology Centre
🇿🇦Port Elizabeth, South Africa
University of Pretoria Oncology Department
🇿🇦Pretoria, South Africa
Mary Potter Oncology Centre
🇿🇦Pretoria, South Africa
Hospital General Universitario de Alicante
🇪🇸Alicante, Spain
ICO Badalona - Hospital Germans Trias i Pujol
🇪🇸Badalona, Spain
Hospital Universitari Quiron Dexeus
🇪🇸Barcelona, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Clinic i Provincial de Barcelona
🇪🇸Barcelona, Spain
Hospital Universitario Materno-Infantil de Canarias
🇪🇸Las Palmas de Gran Canaria, Spain
Tri-Service General Hospital
🇨🇳Taipei, Taiwan
Baskent University Ankara Hospital
🇹🇷Ankara, Turkey
Bezmi Alem Foundation University Medical Faculty Hospital
🇹🇷Istanbul, Turkey
Istanbul University Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Fatih Universitesi Tip Fakultesi
🇹🇷Istanbul, Turkey
Ege University Medical Faculty
🇹🇷Izmir, Turkey
Royal Devon and Exeter Hospital (Wonford)
🇬🇧Exeter, United Kingdom
St James's University Hospital
🇬🇧Leeds, United Kingdom
Derriford Hospital
🇬🇧Plymouth, United Kingdom
University College London Hospital
🇬🇧London, United Kingdom
Mount Vernon Hospital
🇬🇧Stevenage, United Kingdom
The Clatterbridge Cancer Centre
🇬🇧Wirral, United Kingdom
Azienda Ospedaliera Istituti Ospitalieri di Cremona
🇮🇹Cremona, Italy
Ospedale Versilia
🇮🇹Lido di Camaiore, Italy
Seconda Università degli Studi di Napoli
🇮🇹Napoli, Italy
Azienda Ospedaliero Universitaria Pisana
🇮🇹Pisa, Italy
A.O.U. Senese Policlinico Santa Maria alle Scotte
🇮🇹Siena, Italy
Università Campus Bio-Medico di Roma
🇮🇹Roma, Italy
Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Italy
Azienda Ospedaliera Ospedale Treviglio-Caravaggio di Treviglio
🇮🇹Treviglio, Italy
Istituto Nazionale Tumori Regina Elena IRCCS
🇮🇹Roma, Italy
Herlev Hospital
🇩🇰Herlev, Denmark
Odense Universitetshospital
🇩🇰Odense C, Denmark
Mercy Clinic Oklahoma Communities, Inc.
🇺🇸Oklahoma City, Oklahoma, United States
Sharp Memorial Hospital
🇺🇸San Diego, California, United States
Oncology Hematology Care
🇺🇸Cincinnati, Ohio, United States
Henry Ford Health System
🇺🇸Detroit, Michigan, United States
SCRI - Tennessee Oncology
🇺🇸Nashville, Tennessee, United States
CHU Besançon - Hôpital Jean Minjoz
🇫🇷Besancon Cedex, France
Groupe Hospitalier Sud - Hôpital Haut-Lévêque
🇫🇷Pessac, France
CHU de Toulouse - Hôpital Larrey
🇫🇷Toulouse, France
Bristol Haematology & Oncology Centre
🇬🇧Bristol, United Kingdom
Hospital de Caridade de Ijuí
🇧🇷Ijuí, Brazil
CMiP - Centro Mineiro de Pesquisa
🇧🇷Juiz de Fora, Brazil
Liga Norte-Rio-Grandense Contra o Câncer
🇧🇷Natal, Brazil
ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira
🇧🇷São Paulo, Brazil
Oncosinos - Clínica de Oncologia - Hospital Regina
🇧🇷Novo Hamburgo, Brazil
CITO - Centro Integrado de Terapia Onco-Hematológica - Hospital da Cidade de Passo Fundo
🇧🇷Passo Fundo, Brazil
ICO l´Hospitalet - Hospital Duran i Reynals
🇪🇸L'Hospitalet de Llobregat, Spain
Hospital Clinico Universitario Virgen de la Victoria
🇪🇸Malaga, Spain
Centro Integral Oncologico Clara Campal
🇪🇸Madrid, Spain
Holy Cross Hospital Inc.
🇺🇸Fort Lauderdale, Florida, United States
Sutter Gould Medical Foundation
🇺🇸Modesto, California, United States
Hematology Oncology Associates of Rockland
🇺🇸Nyack, New York, United States
University of Texas Health Science Center at Tyler
🇺🇸Tyler, Texas, United States
MultiCare Health System
🇺🇸Tacoma, Washington, United States
The Center for Cancer and Blood Disorders
🇺🇸Fort Worth, Texas, United States
Novant Health Oncology Specialists
🇺🇸Winston-Salem, North Carolina, United States
Centro Oncologico Riojano Integral (Cori)
🇦🇷La Rioja, Argentina
Instituto Gamma
🇦🇷Rosario, Argentina
Centro Medico San Roque S.R.L.
🇦🇷San Miguel de Tucuman, Argentina
Mayo Clinic
🇺🇸Scottsdale , Phoenix, Arizona, United States
National Cancer Center Hospital East
🇯🇵Kashiwa-shi, Japan
Institute of Biomedical Research and Innovation Hospital
🇯🇵Kobe-shi, Japan
NHO Hokkaido Cancer Center
🇯🇵Sapporo-shi, Japan
Chang Gung Memorial Hospital, Linkou
🇨🇳Taoyuan County, Taiwan
UZ Antwerpen
🇧🇪Edegem, Belgium
General Hospital Dubrovnik
🇭🇷Dubrovnik, Croatia
Cancer Institute Hospital of JFCR
🇯🇵Koto-ku, Japan
Kantonsspital Graubuenden
🇨🇭Chur, Switzerland
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
Center for Biomedical Research, LLC
🇺🇸Knoxville, Tennessee, United States
AZ Delta
🇧🇪Roeselare, Belgium
University Clinic for Pulmonary Diseases
🇭🇷Zagreb, Croatia
Kobe City Hospital Organization Kobe City Medical Center General Hospital
🇯🇵Kobe-shi, Japan
Kurume University Hospital
🇯🇵Kurume-shi, Japan
Kinki University Hospital
🇯🇵Osakasayama-shi, Japan
Centre Hospitalier de l'Ardenne
🇧🇪Libramont, Belgium
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Trakya University Medical Faculty
🇹🇷Edirne, Turkey
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
Hokkaido University Hospital
🇯🇵Sapporo-shi, Japan
Yokohama Municipal Citizen's Hospital
🇯🇵Yokohama-shi, Japan